Viscosupplementation Market Size By Product (Single Injection, 3 Injections, 5 Injections), By Source of Origin (Avian Origin, Non-avian Origin), By End-use (Hospitals, Ambulatory Surgical Centers), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2026

Industry Trends

Viscosupplementation Market size was estimated over USD 2.7 billion in 2019 and the industry will grow at 10.1% CAGR through 2026. Growing geriatric population susceptible to osteoarthritis will boost the market growth over the forecast period. For instance, according to a recently published data by the Centers for Disease Control and Prevention (CDC), osteoarthritis affects over 32.5 million adults in the U.S. on an annual basis. Such large patient pool will require medical treatment to reduce the pain, stiffness and swelling caused by osteoarthritis and will ultimately generate the market growth in the coming years.
 

Get more details on this report - Request Free Sample PDF
 

Moreover, increasing demand for minimally invasive viscosupplementation procedures for the treatment of osteoarthritis will enhance the market growth. The minimally invasive treatment replaces synovial fluid by intra-articular injection of hyaluronic acid. As the cost of minimally invasive procedures is significantly less than the conventional procedures, the viscosupplementation industry will witness considerable growth over the forecast period.
 

Get more details on this report - Request Free Sample PDF
 

Increasing prevalence of osteoarthritis coupled with new product launches will drive the market growth

The single injection regimen provides greater physician and patient convenience and hence, is highly preferred over other treatments for viscosupplementation. Osteoarthritis is not only limited to pain and reduced quality of life for patients but also generates high and extra hospital costs.
 

Owing to the rapidly increasing patients suffering from osteoarthritis, the market players will focus on providing single injection viscosupplementation treatments. Moreover, viscosupplementation is a cost-effective treatment option to delay total knee replacement surgery. Hence, low-income countries will majorly focus on viscosupplementation thereby, spurring the market growth. Additionally, launch of new products for the treatment of osteoarthritis will contribute to the industry growth in the upcoming years.
 

Presence of large number of commercialized products for the treatment of osteoarthritis will enhance the segmental growth

Get more details on this report - Request Free Sample PDF
 

The 3 injections segment held a market share of around 48% in 2019 and is anticipated to grow at substantial rate during the forecast period. The 3 injection viscosupplementation treatments are in the market for quite a long time. The segmental growth is attributed to the factors such as high adoption of products and presence of large number of commercialized products for the treatment of osteoarthritis. The viscosupplementation procedure with the help of 3 injections is provided to the patients at weekly intervals. The 3 injections treatment reduces the pain of an individual within few weeks and hence, will ultimately enhance the product demand.
 

Several advantages of viscosupplements with non-avian origin will impel the segmental growth over the forecast period

The non-avian origin segment was valued at around USD 2.1 billion in 2019. The viscosupplements with non-avian origin are the bio-fermentation products produced using bacteria. Owing to the high safety, effectiveness and lower allergenic potential, large number of patients are selecting the viscosupplementation procedures with non-avian source of origin. Moreover, the hyaluronic acid derived from non-avian origin reduces the risks of adverse reactions such as arthralgia, injection-site erythema, swelling, joint warmth and joint effusion.
 

Rising number of hospitals across the globe will contribute to the growth of viscosupplementation market over the analysis period

Get more details on this report - Request Free Sample PDF
 

The hospitals segment is anticipated to expand at a CAGR of 9.8% over the projected years. Increasing number of hospitals across the globe and availability of appropriate viscosupplementation procedures for the patients suffering from osteoarthritis will positively impact the segmental growth.
 

Strong presence of market players and increasing incidence of osteoarthritis across the U.S.

U.S. viscosupplementation market was valued at USD 1.2 billion in 2019 and is expected to register significant growth over the projected years. The country growth is attributed to the increasing number of patients suffering from osteoarthritis and growing elderly population. Moreover, strong presence of the market players offering hyaluronic acid will significantly contribute to the industry growth. Furthermore, rise in the number of healthcare professionals as well as healthcare facilities will prove beneficial for the treatment of people having degenerative joint disease thereby, impelling the market growth.
 

France held a significant share in European market in 2019 and is estimated to expand at a CAGR of 10% over the forecast period. Owing to the high incidence of osteoarthritis in French population, the country will witness momentous market growth in the future. Moreover, strong focus on improving healthcare facilities across the country will further contribute to the market growth.
 

Implementation of several strategies such as new product launches and acquisitions by the major industry players will contribute to the market growth

Some of the prominent players in the viscosupplementation market share are Anika Therapeutics, Inc., Aptissen, Bioventus, Chugai Pharmaceutical Co., Ltd, Johnson & Johnson Services, Inc., Mylan Inc., Zimmer Biomet, Wellchem Pharmaceuticals Pte Ltd. and Genzyme Corporation among others. These market players are majorly focusing on various strategies such as mergers, acquisitions, partnerships, new product launches, collaborations and other market development strategies.
 

Recent industry developments:

• In February 2020, Anika Therapeutics, Inc. completed the acquisition of Arthrosurface that is a privately held manufacturer of preservation solutions and joint surface for active patients. The strategic move will increase the customer base of company thereby, augmenting the market growth.  
   
• In March 2018, Bioventus launched its single injection, hyaluronic acid product in the U.S. market. The strategy helped the company in increasing its geographic presence thereby, augmenting the growth of viscosupplementation industry.      
   

The viscosupplementation industry research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2015 to 2026, for the following segments:

By Product, 2015 – 2026 (USD Million)

• Single Injection
• 3 Injections
• 5 Injections

By Source of Origin, 2015 – 2026 (USD Million)

• Avian Origin
• Non-avian Origin

By End-use, 2015 – 2026 (USD Million)

• Hospitals
• Ambulatory Surgical Centers
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia